
Burning Rock Biotech Ltd
NASDAQ:BNR

Intrinsic Value
Burning Rock Biotech Ltd. engages in the investment of medical fields. [ Read More ]
The intrinsic value of one
BNR
stock under the Base Case scenario is
6.99
USD.
Compared to the current market price of 0.97 USD,
Burning Rock Biotech Ltd
is
Undervalued by 86%.


Whether you're assessing long-term stability or short-term opportunities, Historical Valuation serves as a vital tool to enhance your investment approach, enabling you to make more informed investment decisions.
Sign up
to access Burning Rock Biotech Ltd's intrinsic value history.
No restrictions, no limits.
All stocks, all tools.
There are two methods to calculate the Intrinsic Value of a stock: DCF Valuation and Relative Valuation. We take the average of these two methods to estimate the intrinsic value as accurately as possible. You can see the Intrinsic Value of a stock at the top of this page.
DCF Value
Discounted Cash Flow
Fundamental Analysis
Balance Sheet Decomposition
Burning Rock Biotech Ltd
Current Assets | 1.1B |
Cash & Short-Term Investments | 733m |
Receivables | 202m |
Other Current Assets | 155m |
Non-Current Assets | 241m |
Long-Term Investments | 505k |
PP&E | 222m |
Intangibles | 1.2m |
Other Non-Current Assets | 17m |
Current Liabilities | 353m |
Accounts Payable | 24.6m |
Accrued Liabilities | 180m |
Other Current Liabilities | 149m |
Non-Current Liabilities | 10.1m |
Other Non-Current Liabilities | 10.1m |
BNR Profitability Score
Profitability Due Diligence
Burning Rock Biotech Ltd's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

Score
Burning Rock Biotech Ltd's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
BNR Solvency Score
Solvency Due Diligence
Burning Rock Biotech Ltd's solvency score is 47/100. The higher the solvency score, the more solvent the company is.

Score
Burning Rock Biotech Ltd's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BNR Price Targets Summary
Burning Rock Biotech Ltd
According to Wall Street analysts, the average 1-year price target for
BNR
is 5.71 USD
.
Shareholder Return
BNR Price
Burning Rock Biotech Ltd
Average Annual Return | -29.45% |
Standard Deviation of Annual Returns | 40.61% |
Max Drawdown | -98% |
Market Capitalization | 99.6m USD |
Shares Outstanding | 102 675 000 |
Percentage of Shares Shorted | 5.22% |
Company Profile


Country
Industry
Market Cap
Dividend Yield
Description
Burning Rock Biotech Ltd. engages in the investment of medical fields. The company is headquartered in Guangzhou, Guangdong. The company went IPO on 2020-06-12. The firm operates three segments. Central Laboratory Business segment is engaged in the sales of cancer therapy selection test to individual patients. In-Hospital Business segment is engaged in the sales of reagent kits and the provision of the facilitation services for the sale of laboratory equipment to hospitals. Pharma Research and Development Services segment provide services to companies primarily in relation to the development of targeted therapies and immunotherapies for various types of cancer, and to hospitals for their studies on cancer diagnosis and treatment. Its products include OncoScreen Plus and LungPlasma. Its NGS-based cancer therapy selection tests applicable to a broad range of cancer types, including lung cancer, prostate cancer, breast cancer and others. The firm mainly conducts its businesses in the China market.
Contact
IPO
Employees
Officers
The intrinsic value of one
BNR
stock under the Base Case scenario is
6.99
USD.
Compared to the current market price of 0.97 USD,
Burning Rock Biotech Ltd
is
Undervalued by 86%.